Pfizer's Paxlovid not included in China's national insurance

Summary by CTV News

China's health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.

Published 5 months ago · Beijing, China

News Articles

More Filters

All

Left

Center

Right

Reuters

China says talks to include Paxlovid in its insurance drug list fail

China will not include Pfizer Inc's Paxlovid in an update to its list of medicines covered by basic medical insurance schemes as the U.S. firm quoted a high price for the COVID-19 drug, China's Healthcare Security Administration (NHSA) said on Sunday.

5 months ago·United Kingdom

Read Full Article

CTV News

Pfizer's Paxlovid not included in China's national insurance

5 months ago·Toronto, Canada

Read Full Article

Associated Press News

Pfizer's Paxlovid not included in China's national insurance

China will not include Pfizer’s COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price, saying it was too expensive.

5 months ago·United States

Read Full Article

abc News

Pfizer's Paxlovid not included in China's national insurance

China will not include Pfizer’s COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price, saying it was too expensive

5 months ago·United States

Read Full Article

South China Morning Post

China and Pfizer fail to reach Paxlovid public insurance deal

The antiviral has not been included in a national register that would have brought the cost down to consumers.

5 months ago·Hong Kong

Read Full Article

KIFI

Pfizer's Paxlovid not included in China's national insurance

By HUIZHONG WU Associated Press TAIPEI, Taiwan (AP) — China will not include Pfizer’s COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. Paxlovid, an oral medicine developed by New York-based drugmaker Pfizer, has been widely sought after in China since the country began phasing out its “zero-COVID” restrictions and infections…

5 months ago·Idaho Falls, United States

Read Full Article